The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
Canada Intensifies Scrutiny of AI Risks in Banking Sector
Jul 13, 2026 by
CPI
Second Circuit Upholds Injunction Against Nielsen in Radio Ratings Antitrust Fight
Jul 13, 2026 by
CPI
TransDigm Abandons $960M Stellant Systems Acquisition After US Antitrust Pushback
Jul 13, 2026 by
CPI
Administration Expands Effort to Keep AI-Driven Electricity Costs Off Consumer Bills
Jul 13, 2026 by
CPI
Mexican Lawmakers Move to Challenge Sony Over Potential PlayStation Store Monopoly
Jul 13, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Due Process
Jul 7, 2026 by
CPI
The Hart‑Scott‑Rodino Act at Fifty: Procedure, Thresholds, Serial Acquisitions, and Industry Dynamics
Jul 7, 2026 by
Ginger Zhe Jin, Mario Leccese, Daniel Sokol, Liad Wagman & Mengyi Zhong
Due Process In Competition Cases: Reflections As Of 2026
Jul 7, 2026 by
Ian Forrester & Pablo Trevisan
When Referees Become Reformers: Due Process and Constitutional Considerations in Competition Market Investigations
Jul 7, 2026 by
John Taladay & Christine Ryu-Naya
Procedural Fairness in Antitrust Enforcement: A Comparative Analysis
Jul 7, 2026 by
J. Mark Gidley & Daniel Sokol